Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact
复制标题
DOI：
10.1016/s0049-3848(10)70014-1
复制
发表时间：
2010-04-01
影响因子：
7.5
通讯作者：
Rodeghiero, F.
中科院分区：
文献类型：
--
作者：
Elice, F.;Rodeghiero, F.
近年来，肿瘤血管和肿瘤相关新生血管已成为抗肿瘤治疗的主要靶点。除了已经获得美国食品和药物管理局(FDA)批准用于临床的药物(沙利度胺、来那度胺、贝伐单抗、舒尼替尼、索拉非尼)外，还有许多其他药物正在进行临床试验。血管生成抑制剂，特别是血管内皮生长因子(VEGF)途径的抑制剂，已经显示出显著的血管并发症，包括血栓栓子和出血事件。确定出血并发症的临床影响(与对照组相比，出血率增加)和了解这种毒性的发病机制是非常重要的，以便评估许多研究在癌症患者治疗中使用抗血管生成药物的结果。(C)2010爱思唯尔有限公司。保留所有权利。
Tumor vasculature and tumor-associated neo-angiogenesis have recently become major targets of antineoplastic therapy. Beside the agents which have already obtained US Food and Drug Administration (FDA) approval for clinical use (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib), many others are being tested in clinical trials. Angiogenesis inhibitors, in particular inhibitors of the vascular endothelial growth factor (VEGF) pathway, have shown significant vascular complications, including both thromboembolic and bleeding events. The definition of the clinical impact of bleeding complications (increase in the rate of hemorrhages in comparison with the control group) and the knowledge of the pathogenesis of this toxicity are very important in order to evaluate the results of many studies using antiangiogenic agents in the treatment of cancer patients. (C) 2010 Elsevier Ltd. All rights reserved.